Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on October 16, 2006.
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 53
- Registration Number
- NCT02318693
Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2019-07-01
- Lead Sponsor
- Kansai Electric Power Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT02312063
- Locations
- 🇯🇵
Kansai Electric Power Hospital, Osaka, Japan
🇯🇵Saiseikai Noe Hospital Osaka, Osaka, Japan
Effects of Sitaglpitin on Endothelial Function During the OGTT in T2DM
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Dokkyo Medical University
- Target Recruit Count
- 30
- Registration Number
- NCT02301806
- Locations
- 🇯🇵
Dokkyo Medical University, Mibu, Tochigo, Japan
Sitagliptin and Brown Adipose Tissue
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- Ingrid Jazet
- Target Recruit Count
- 30
- Registration Number
- NCT02294084
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 461
- Registration Number
- NCT02284893
- Locations
- 🇿🇦
Research Site, Soweto, South Africa
Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI
- Conditions
- Interventions
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2016-10-05
- Lead Sponsor
- University of Missouri-Columbia
- Registration Number
- NCT02263677
- Locations
- 🇺🇸
University of Missouri-Columbia: Diabetes Center, Columbia, Missouri, United States
Sitagliptin and Glucagon Counterregulation
- First Posted Date
- 2014-10-03
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- Lund University
- Target Recruit Count
- 28
- Registration Number
- NCT02256189
- Locations
- 🇸🇪
Skane University Hospital Malmö, Malmö, Sweden
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 308
- Registration Number
- NCT02254291
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Japan
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
- Conditions
- Interventions
- First Posted Date
- 2014-08-26
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 291
- Registration Number
- NCT02226003
A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients
- Conditions
- Interventions
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT02202161
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.